Bionomics (BNOX)
(Real Time Quote from BATS)
$0.98 USD
-0.03 (-2.97%)
Updated Apr 30, 2024 12:14 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNOX 0.98 -0.03(-2.97%)
Will BNOX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BNOX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNOX
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals
Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%
BNOX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate
Bears are Losing Control Over Bionomics Limited Unsponsored ADR (BNOX), Here's Why It's a 'Buy' Now
Can Bionomics Limited Unsponsored ADR (BNOX) Climb 329% to Reach the Level Wall Street Analysts Expect?
Other News for BNOX
12 Health Care Stocks Moving In Tuesday's After-Market Session
Buy Rating Affirmed for Bionomics’ BNC210 Following Promising PTSD Study Results
Bionomics’s BNC210 Shows Promise for PTSD Treatment: A Buy Rating Analysis
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
Bionomics' BNC210 shows significant improvement in PTSD